Literature DB >> 35045253

Activation of E6AP/UBE3A-Mediated Protein Ubiquitination and Degradation Pathways by a Cyclic γ-AA Peptide.

Bo Huang1, Li Zhou2, Ruochuan Liu2, Lei Wang1, Songyi Xue1, Yan Shi1, Geon Ho Jeong2, In Ho Jeong2, Sihao Li1, Jun Yin2, Jianfeng Cai1.   

Abstract

Manipulating the activities of E3 ubiquitin ligases with chemical ligands holds promise for correcting E3 malfunctions and repurposing the E3s for induced protein degradation in the cell. Herein, we report an alternative strategy to proteolysis-targeting chimeras (PROTACs) and molecular glues to induce protein degradation by constructing and screening a γ-AA peptide library for cyclic peptidomimetics binding to the HECT domain of E6AP, an E3 ubiquitinating p53 coerced by the human papillomavirus and regulating pathways implicated in neurodevelopmental disorders such as Angelman syndrome. We found that a γ-AA peptide P6, discovered from the affinity-based screening with the E6AP HECT domain, can significantly stimulate the ubiquitin ligase activity of E6AP to ubiquitinate its substrate proteins UbxD8, HHR23A, and β-catenin in reconstituted reactions and HEK293T cells. Furthermore, P6 can accelerate the degradation of E6AP substrates in the cell by enhancing the catalytic activities of E6AP. Our work demonstrates the feasibility of using synthetic ligands to stimulate E3 activities in the cell. The E3 stimulators could be developed alongside E3 inhibitors and substrate recruiters such as PROTACs and molecular glues to leverage the full potential of protein ubiquitination pathways for drug development.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35045253      PMCID: PMC8889547          DOI: 10.1021/acs.jmedchem.1c01922

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  Full orthogonality between Dde and Fmoc: the direct synthesis of PNA--peptide conjugates.

Authors:  Juan Jose Díaz-Mochón; Laurent Bialy; Mark Bradley
Journal:  Org Lett       Date:  2004-04-01       Impact factor: 6.005

2.  Ubiquitin as a central cellular regulator.

Authors:  Daniel Finley; Aaron Ciechanover; Alexander Varshavsky
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  Targeting HECT-type E3 ligases - insights from catalysis, regulation and inhibitors.

Authors:  Valentina Fajner; Elena Maspero; Simona Polo
Journal:  FEBS Lett       Date:  2017-08-20       Impact factor: 4.124

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

5.  Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade.

Authors:  L Huang; E Kinnucan; G Wang; S Beaudenon; P M Howley; J M Huibregtse; N P Pavletich
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

6.  Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination.

Authors:  S Kumar; A L Talis; P M Howley
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

7.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

8.  Sulfono-γ-AApeptides as Helical Mimetics: Crystal Structures and Applications.

Authors:  Peng Sang; Yan Shi; Bo Huang; Songyi Xue; Timothy Odom; Jianfeng Cai
Journal:  Acc Chem Res       Date:  2020-09-17       Impact factor: 22.384

Review 9.  A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders.

Authors:  Arlene J George; Yarely C Hoffiz; Antoinette J Charles; Ying Zhu; Angela M Mabb
Journal:  Front Genet       Date:  2018-02-14       Impact factor: 4.599

Review 10.  Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets.

Authors:  Lynn Bedford; James Lowe; Lawrence R Dick; R John Mayer; James E Brownell
Journal:  Nat Rev Drug Discov       Date:  2010-12-10       Impact factor: 84.694

View more
  1 in total

1.  A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.

Authors:  Songyi Xue; Xinling Wang; Lei Wang; Wei Xu; Shuai Xia; Lujia Sun; Shaohui Wang; Ning Shen; Ziqi Yang; Bo Huang; Sihao Li; Chuanhai Cao; Laurent Calcul; Xingmin Sun; Lu Lu; Jianfeng Cai; Shibo Jiang
Journal:  Cell Discov       Date:  2022-09-08       Impact factor: 38.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.